Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

WILLIAM J GRADISHAR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1437187929
CMS profile
155302
Location
CHICAGO, IL

General Payments · PY2018–2024

$276,318.93

  • Reported across 227 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$43,827.74

34 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $40,822.50 19
Travel and Lodging $1,798.74 6
Food and Beverage $1,053.27 8
Honoraria $153.23 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Genentech USA, Inc. $12,783.09 7
Acerta Pharma LLC $10,750.85 9
Stemline Therapeutics Inc. $7,038.88 7
Daiichi Sankyo Inc. $4,452.50 3
AstraZeneca UK Limited $2,190.00 2
Gilead Sciences, Inc. $1,920.00 1
Lilly USA, LLC $1,800.00 1
Eli Lilly and Company $1,800.00 1
Genentech, Inc. $990.00 1
BioNTech SE $79.00 1
PFIZER INC. $23.42 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $45,124.07 42
PY2019 $50,991.28 46
PY2020 $27,079.00 19
PY2021 $38,983.30 27
PY2022 $40,502.79 30
PY2023 $29,810.75 29
PY2024 $43,827.74 34

Payment records · PY2024 (34)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $685.00 02/20/2024 Consulting Fee Undisputed 01/23/2026 1104530800 CMS
AstraZeneca Pharmaceuticals LP $13.68 03/04/2024 Travel and Lodging Undisputed 01/23/2026 1105707980 CMS
AstraZeneca Pharmaceuticals LP $49.06 03/13/2024 Travel and Lodging Undisputed 01/23/2026 1105813085 CMS
AstraZeneca Pharmaceuticals LP $106.89 04/07/2024 Food and Beverage Undisputed 01/23/2026 1105677441 CMS
AstraZeneca Pharmaceuticals LP $1,370.00 07/01/2024 Consulting Fee Undisputed 01/23/2026 1104371581 CMS
AstraZeneca Pharmaceuticals LP $4,510.00 11/12/2024 Consulting Fee Undisputed 01/23/2026 1104332100 CMS
AstraZeneca Pharmaceuticals LP $46.22 12/11/2024 Food and Beverage Undisputed 01/23/2026 1105241157 CMS
AstraZeneca Pharmaceuticals LP $2,740.00 12/19/2024 Consulting Fee Undisputed 01/23/2026 1104471794 CMS
AstraZeneca Pharmaceuticals LP $1,230.00 12/20/2024 Consulting Fee Undisputed 01/23/2026 1105754775 CMS
AstraZeneca UK Limited $2,055.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1093886830 CMS
AstraZeneca UK Limited $135.00 12/11/2024 Food and Beverage Undisputed 01/23/2026 1094028930 CMS
BioNTech SE $79.00 05/31/2024 Food and Beverage Undisputed 01/23/2026 1150660412 CMS
Daiichi Sankyo Inc. $1,712.50 08/14/2024 Consulting Fee Undisputed 01/23/2026 1089427683 CMS
Daiichi Sankyo Inc. $685.00 09/18/2024 Consulting Fee Undisputed 01/23/2026 1089427687 CMS
Daiichi Sankyo Inc. $2,055.00 10/30/2024 Consulting Fee Undisputed 01/23/2026 1089427685 CMS
Eli Lilly and Company $1,800.00 12/04/2024 Consulting Fee Undisputed 01/23/2026 1135470285 CMS
Genentech USA, Inc. $66.00 02/29/2024 Travel and Lodging Undisputed 01/23/2026 1133133041 CMS
Genentech USA, Inc. $357.42 02/29/2024 Travel and Lodging Undisputed 01/23/2026 1133133045 CMS
Genentech USA, Inc. $202.05 02/29/2024 Food and Beverage Undisputed 01/23/2026 1133133049 CMS
Genentech USA, Inc. $1,289.16 02/29/2024 Travel and Lodging Undisputed 01/23/2026 1133133053 CMS
Genentech USA, Inc. $6,840.00 02/29/2024 Consulting Fee Undisputed 01/23/2026 1133133057 CMS
Genentech USA, Inc. $228.46 12/10/2024 Food and Beverage Undisputed 01/23/2026 1133133032 CMS
Genentech USA, Inc. $3,800.00 12/10/2024 Consulting Fee Undisputed 01/23/2026 1133133036 CMS
Genentech, Inc. $990.00 06/07/2024 Consulting Fee Undisputed 01/23/2026 1133133061 CMS
Gilead Sciences, Inc. $1,920.00 12/30/2024 Consulting Fee Undisputed 01/23/2026 1133600107 CMS
Lilly USA, LLC $1,800.00 02/05/2024 Consulting Fee Undisputed 01/23/2026 1135482207 CMS
PFIZER INC. $23.42 01/12/2024 Travel and Lodging Undisputed 01/23/2026 1131484167 CMS
Stemline Therapeutics Inc. $1,560.00 02/02/2024 Consulting Fee Undisputed 01/23/2026 1142965952 CMS
Stemline Therapeutics Inc. $390.00 04/12/2024 Consulting Fee Undisputed 01/23/2026 1142965957 CMS
Stemline Therapeutics Inc. $137.72 05/30/2024 Food and Beverage Undisputed 01/23/2026 1142965966 CMS
Stemline Therapeutics Inc. $2,340.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 1142965960 CMS
Stemline Therapeutics Inc. $153.23 06/28/2024 Honoraria Undisputed 01/23/2026 1142965963 CMS
Stemline Therapeutics Inc. $2,340.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 1142965974 CMS
Stemline Therapeutics Inc. $117.93 12/09/2024 Food and Beverage Undisputed 01/23/2026 1142965970 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.